Unknown

Dataset Information

0

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.


ABSTRACT: The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study where mCRC patients received first-line fluoropyrimidine-based chemotherapy combined with either bevacizumab (188 patients with KRAS wild-type or mutated tumors) or cetuximab (101 patients with KRAS wild-type tumors) between January 2009 and December 2013. The Kaplan-Meier method was used for survival analysis. Cox proportional hazards model was used for estimating the prognostic and predictive values of clinicopathological characteristics. No statistically significant difference was observed between the bevacizumab and cetuximab groups in terms of median progression-free survival (PFS) (10.6 vs 8.7 months, P?=?0.317), median overall survival (OS) (27.7 vs 28.3 months, P?=?0.525), or overall response rate (43.1% vs 53.5%, P?=?0.108). For the subset of patients with peritoneal dissemination, bevacizumab-based triplet appears to be superior to cetuximab-based triplet as measured by PFS (9.6 vs 6.1 months) and OS (26.3 vs 12.7 months), but not for patients without peritoneal dissemination (PFS, 10.6 vs 9.1 months; OS, 27.9 vs 30.7 months) (all unadjusted and adjusted interaction P?

SUBMITTER: Bai L 

PROVIDER: S-EPMC5181797 | biostudies-other | 2016 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.

Bai Long L   Wang Feng F   Li Zhe-Zhen ZZ   Ren Chao C   Zhang Dong-Sheng DS   Zhao Qi Q   Lu Yun-Xin YX   Wang De-Shen DS   Ju Huai-Qiang HQ   Qiu Miao-Zhen MZ   Wang Zhi-Qiang ZQ   Wang Feng-Hua FH   Xu Rui-Hua RH  

Medicine 20161201 51


The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study where mCRC patients received first-line fluoropyrimidine-based chemotherapy combined with either bevacizumab (188 patients with KRAS wild-type or mutated tumors) or cetuximab (101 patients with KRAS wil  ...[more]

Similar Datasets

| S-EPMC8124114 | biostudies-literature
| S-EPMC5764984 | biostudies-literature
| S-EPMC10807607 | biostudies-literature
| S-EPMC3174848 | biostudies-literature
| S-EPMC6738101 | biostudies-literature
| S-EPMC4893985 | biostudies-literature
| S-EPMC7666202 | biostudies-literature
| S-EPMC9022943 | biostudies-literature
| S-EPMC6440242 | biostudies-literature
| S-EPMC6110978 | biostudies-literature